~~<i id='8091A41570'><strike id='8091A41570'><tt id='8091A41570'><pre id='8091A41570'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：entertainment 2025-09-30 21:58:14 - browse：276

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Pregnancy discrimination could be enabled by AI

hotspot

leisure time

knowledge

hotspot

Wikipedia

STEFANIREYNOLDS/AFPviaGettyImagesUnderstandhowscience,healthpolicy,andmedicineshapetheworldeveryday.

WSS

Medical mystery: When a cough is not just a cough

Senators start work on Medicare physician payment reform

After sickle

What should King Charles tell the public about his cancer?

Medical mystery: When a cough is not just a cough

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

focus

hotspot

The high cost of giving birth even with insurance

Key House Republican on health care plans exit from Congress

Continuity nursing helped my family in our darkest PICU moments

Biden report: The neurospychology of memory and aging

Hepatitis C has a cure — but many Americans still lack access to it

SCOTUS to consider access to abortion pill mifepristone

Activists slam private health insurers over coverage restrictions

Industry veterans launch new biotech VC with $310M

Drug repurposing or repositioning? The language matters

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

How digital tools helped lower hypertension in marginalized patients

Medical mystery: When a cough is not just a cough

Radiology is caught between AI's potential and concern for patients

Readout LOUD podcast: How biotech is using artificial intelligence

SCOTUS to consider access to abortion pill mifepristone

AI models in health care face new federal disclosure requirements

leisure time

knowledge

hotspot

Wikipedia